Quiet but ambitious, EndeavorRide from Shionogi turns ADHD therapy into an app

Reviewed: ad hoc news Software & Services desk. Edited and checked on 2026-06-18, 21:39. Details in the imprint.

EndeavorRide from Shionogi looks at first glance like a colorful tablet game, but for children with ADHD in Japan it is an officially approved digital therapeutic that demands focus, taps, and quick decisions in tightly timed sessions that feel more like play than treatment.

What EndeavorRide actually is

Shionogi developed EndeavorRide as a prescription digital therapeutic app for pediatric ADHD patients aged 6 to 17 in Japan, based on Akili’s Selective Stimulus Management Engine technology that targets cognitive control networks in the brain.

The software delivers structured, game-like tasks that require children to track moving objects, react to targets, and ignore distractions within short daily sessions. Each tap, miss, and pause is logged, turning play into a stream of therapeutic data.

How the digital therapy works day to day

In everyday use, the child sits with a tablet or smartphone, launches EndeavorRide, and is guided through around 25 minutes of focused gameplay, usually five days per week over several weeks as part of a prescribed course.

The app dynamically adjusts difficulty based on performance, so tasks quietly become more demanding as concentration improves, while built-in limits stop children from endlessly playing and protect against overuse.

Clinical backing and approval in Japan

Before approval, EndeavorRide underwent a Phase 3 clinical trial in Japan with 164 children and adolescents, where it showed statistically significant improvement on standard ADHD attention scales compared with a control group.

On the back of these data, regulators cleared it as the first officially approved digital therapeutic support tool for pediatric ADHD in Japan, giving doctors a new non-drug option alongside medication and behavioral therapy.

Where the app shines and where it annoys

The elegant part is how EndeavorRide turns repetitive cognitive training into a visually rich, fast, and almost arcade-like experience, which many families may find easier to stick with than paper-based exercises or abstract tasks.

What can be sobering, though, is that the app must still be used very consistently to have an effect, and parents need to manage access, device time, and motivation - there is no magic switch that fixes attention overnight.

How EndeavorRide fits into care

Doctors in Japan can prescribe EndeavorRide as an adjunctive therapy, meaning it is intended to support, not replace, established treatments such as stimulant medication or structured behavioral programs.

For some families worried about side effects of drugs, the app offers a quieter, non-pharmacological option that can be tried early, potentially delaying or complementing the need for higher doses of medication.

Pricing and availability in the home market

EndeavorRide is currently available only in Japan, with access controlled through medical prescription so families cannot simply download and start without a healthcare professional involved in the process.

Shionogi positions the software as a reimbursable medical device rather than a consumer wellness app, which means price and coverage depend on Japan’s healthcare reimbursement decisions rather than app-store logic.

Why Shionogi is betting on digital therapeutics

For Shionogi, EndeavorRide is part of a broader push into healthcare services that extend beyond pills, aiming to combine pharmaceuticals, diagnostics, and digital tools into more comprehensive treatment ecosystems.

This fits a consistent strategy: the company has been investing in infectious disease platforms, new vaccine technologies, and partnerships in data-driven care to diversify revenue as some older drug patents face pressure.

Context for investors and listing note

Investors watching Shionogi will likely see EndeavorRide as an early test of how much value regulated digital therapeutics can add alongside traditional drugs, especially in chronic conditions such as ADHD.

Shares of Shionogi & Co., Ltd. (JP3347200002) trade on the Tokyo Stock Exchange under the code 4507 in Japanese yen.

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.